APA (7th ed.) Citation

McKenzie, M., Chi, K., Neville, A., Ellard, S., Baerg, B., Ruether, D., . . . Lukka, H. (2006). 34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP). Radiotherapy & Oncology, 80, S10. https://doi.org/10.1016/s0167-8140(06)80775-9

Chicago Style (17th ed.) Citation

McKenzie, M., et al. "34 Phase 2 Study of Neoadjuvant Docetaxel and Androgen Suppression (AS) Plus Radiation Therapy (RT) for High Risk Localized Prostate Cancer (HRLCaP)." Radiotherapy & Oncology 80 (2006): S10. https://doi.org/10.1016/s0167-8140(06)80775-9.

MLA (9th ed.) Citation

McKenzie, M., et al. "34 Phase 2 Study of Neoadjuvant Docetaxel and Androgen Suppression (AS) Plus Radiation Therapy (RT) for High Risk Localized Prostate Cancer (HRLCaP)." Radiotherapy & Oncology, vol. 80, 2006, p. S10, https://doi.org/10.1016/s0167-8140(06)80775-9.